Physician profile
Mitchell Jamison
NPI 1912459637
$729.76
in general payments reported to CMS, 2019-2025
12 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $58.08 · 2023: $25.40 · 2024: $127 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $285.23 | 2021-2024 | Cardiomems |
| Edwards Lifesciences Corporation | $125.34 | 2025 | Evoque |
| Boston Scientific Corporation | $97.50 | 2022-2025 | Watchman |
| Amgen INC. | $45.56 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.65 | 2021-2025 | Lifevest |
| Heartflow, INC. | $25.40 | 2023 | Ffrct |
| Merck Sharp & Dohme LLC | $25.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.94 | 2022 | |
| Medtronic, INC. | $18.73 | 2021 | |
| Atricure, INC. | $14.40 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Jamison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.